DECLINING RATES OF FIXED-DOSE COMBINATION PILLS FOR HYPERTENSION IN GERMANY FROM 2016 TO 2023

Goetzinger, F; Kieble, M; Laufs, U; Mahfoud, F; Schulz, M

DECLINING RATES OF FIXED-DOSE COMBINATION PILLS FOR HYPERTENSION IN GERMANY FROM 2016 TO 2023

Goetzinger, F Kieble, M Laufs, U Mahfoud, F Schulz, M

Permalink

Publisher:: LIPPINCOTT WILLIAMS & WILKINS
Publication Type:: Conference Abstract
Citation:: JOURNAL OF HYPERTENSION, 2024, 42, (Suppl 1)
Issue Date:: 2024-05

Closed Access

	Filename	Description	Size
	declining_rates_of_fixed_dose_combination_pills.705.pdf	Published version	1.51 MB		View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Goetzinger, F
dc.contributor.author	Kieble, M
dc.contributor.author	Laufs, U
dc.contributor.author	Mahfoud, F
dc.contributor.author	Schulz, M https://orcid.org/0000-0002-5876-7322
dc.date	2024-05-31
dc.date.accessioned	2024-10-24T00:19:24Z
dc.date.available	2024-10-24T00:19:24Z
dc.date.issued	2024-05
dc.identifier.citation	JOURNAL OF HYPERTENSION, 2024, 42, (Suppl 1)
dc.identifier.issn	0263-6352
dc.identifier.issn	1473-5598
dc.identifier.uri	http://hdl.handle.net/10453/181562
dc.description.abstract	<jats:sec> <jats:title>Objective:</jats:title> <jats:p>Current guidelines recommend the usage of fixed-dose combination (FDC) pills in primary and secondary prevention of cardiovascular diseases. Current data on the implementation of these recommendations in German clinical practice are scarce. The objective was to assess the use of antihypertensive FDCs in Germany from 2016-2023.</jats:p> </jats:sec> <jats:sec> <jats:title>Design and method:</jats:title> <jats:p>We analysed claims data from the German Institute for Drug Use Evaluation from January of 2016 to September of 2023, containing information on dispensed drugs in an outpatient care setting of approx. 87% of the German population (excluding private insurance) and evaluated the use of antihypertensive FDC pills according to time, age of the insured persons, and active substances contained in the FDC.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>The use of FDC pills decreased from 2016 to 2022 from 22.2 million packages to 15.6 million packages, while the absolute number of antihypertensives prescribed increased from 143.8 million packages to 155.9 million packages. Consequently, the proportion of FDC pills in all antihypertensives decreased from 15.4% in 2016 to 10.0% in 2022. The amount of hydrochlorothiazide (HCT) containing FDC pills decreased from 2016 to 2022 (from 18.9 million packages to 11.0 million packages), while the amount of FDC pills that do not contain HCT increased from 2016 to 2022 (from 3.3 million packages to 4.7 million packages). Use of FDC pills has been declining in all age groups. FDC pills are used infrequently in patients over 80 years of age.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Despite guideline recommendations, use of antihypertensive FDC pills in Germany is declining, showing continuing guideline inertia. The decrease is mainly driven by decreased prescriptions of HCT-containing FDC pills. Assumed higher medication cost for FDC compared to single pills and fear of non-melanoma skin cancer for HCT are potential reasons. Use of FDC pills should be advised and implemented in outpatient care in Germany.</jats:p> </jats:sec>
dc.language	en
dc.publisher	LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof	JOURNAL OF HYPERTENSION
dc.relation.ispartof	33rd European Meeting on Hypertension and Cardiovascular Renal Protection (ESH)
dc.relation.isbasedon	10.1097/01.hjh.0001022152.56643.c7
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, 1116 Medical Physiology
dc.subject.classification	Cardiovascular System & Hematology
dc.subject.classification	3201 Cardiovascular medicine and haematology
dc.subject.classification	3202 Clinical sciences
dc.title	DECLINING RATES OF FIXED-DOSE COMBINATION PILLS FOR HYPERTENSION IN GERMANY FROM 2016 TO 2023
dc.type	Conference Abstract
utslib.citation.volume	42
utslib.location.activity	GERMANY, Berlin
utslib.for	1102 Cardiorespiratory Medicine and Haematology
utslib.for	1103 Clinical Sciences
utslib.for	1116 Medical Physiology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2024-10-24T00:19:22Z
pubs.finish-date	2024-06-03
pubs.issue	Suppl 1
pubs.publication-status	Published
pubs.start-date	2024-05-31
pubs.volume	42
utslib.citation.issue	Suppl 1

Abstract:

Objective: Current guidelines recommend the usage of fixed-dose combination (FDC) pills in primary and secondary prevention of cardiovascular diseases. Current data on the implementation of these recommendations in German clinical practice are scarce. The objective was to assess the use of antihypertensive FDCs in Germany from 2016-2023. Design and method: We analysed claims data from the German Institute for Drug Use Evaluation from January of 2016 to September of 2023, containing information on dispensed drugs in an outpatient care setting of approx. 87% of the German population (excluding private insurance) and evaluated the use of antihypertensive FDC pills according to time, age of the insured persons, and active substances contained in the FDC. Results: The use of FDC pills decreased from 2016 to 2022 from 22.2 million packages to 15.6 million packages, while the absolute number of antihypertensives prescribed increased from 143.8 million packages to 155.9 million packages. Consequently, the proportion of FDC pills in all antihypertensives decreased from 15.4% in 2016 to 10.0% in 2022. The amount of hydrochlorothiazide (HCT) containing FDC pills decreased from 2016 to 2022 (from 18.9 million packages to 11.0 million packages), while the amount of FDC pills that do not contain HCT increased from 2016 to 2022 (from 3.3 million packages to 4.7 million packages). Use of FDC pills has been declining in all age groups. FDC pills are used infrequently in patients over 80 years of age. Conclusions: Despite guideline recommendations, use of antihypertensive FDC pills in Germany is declining, showing continuing guideline inertia. The decrease is mainly driven by decreased prescriptions of HCT-containing FDC pills. Assumed higher medication cost for FDC compared to single pills and fear of non-melanoma skin cancer for HCT are potential reasons. Use of FDC pills should be advised and implemented in outpatient care in Germany.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/181562